Assertio (ASRT) Insider William Mckee Sells 5,415 Shares

Mckee's Recent Sale of ASRT Shares

William Mckee sold 5,415 shares of ASRT (Assertio Holdings Inc.) on June 16, 2026. This sale comes amid a series of insider transactions at the company. The shares were sold when the stock was priced at $23.50, close to its 52-week high.

Other Insiders Join Mckee

On the same day, several other insiders at ASRT also sold shares. CEO Mark Reisenauer sold 98,748 shares, while EVP General Counsel Sam Schlessinger sold 68,285 shares. Paul Schwichtenberg, the President and COO, sold 78,811 shares, and Ajay Patel, the EVP and CFO, sold 15,942 shares. Heather Mason and Emany Sravan Kumar also participated in the selling, with Mason offloading 42,081 shares and Kumar selling 7,168 shares.

How ASRT Stock Has Traded

ASRT shares are currently trading at $23.50, which is at the upper end of its recent range. The stock has shown resilience, hitting a 52-week high of $23.50 recently. This performance may reflect investor sentiment in the healthcare sector, particularly in specialty and generic drug manufacturers.

What ASRT Does

Assertio Holdings, Inc. is a pharmaceutical company based in Lake Forest, Illinois. It focuses on providing various products to patients in the U.S., including treatments for rheumatoid arthritis and migraine pain. The recent insider selling could suggest a strategic decision by executives amid the company's market positioning.

What to Watch at ASRT

Investors should keep an eye on upcoming earnings reports and any further insider transactions. The recent sales by executives might provide insights into the company's future direction. ASRT's next earnings date has not been disclosed yet, but the ongoing insider activity might signal important developments ahead.